An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology

Abstract

The peptide somatostatin (SRIF) has important physiological effects (mostly inhibitory) which have formed the basis for the clinical use of SRIF compounds. SRIF binding to its five G-protein coupled receptors leads to the modulation of multiple transduction pathways. However, our current understanding of signalling exerted by receptors endogenously expressed in different cells/tissues reflects a rather complicated picture. On the other hand, the complexity of SRIF receptor signalling in pathologies, including pituitary and nervous system diseases, may be studied not only as alternative intervention points for the modulation of SRIF function but also to exploit new chemical space for drug-like molecules.